8-K: Charles River Labs CFO Resigns, Interim Appointed

Charles River Laboratories announced the resignation of its CFO, Flavia H. Pease, effective September 29, 2025, with Michael G. Knell appointed as interim CFO.

Summary

• Flavia H. Pease informed Charles River Laboratories International, Inc. of her intention to resign as Corporate Executive Vice President, Chief Financial Officer, effective September 29, 2025.
• Ms. Pease's decision to resign is not due to any disagreements with the Company regarding its financial statements, internal controls, operations, policies, or practices.
• Michael G. Knell, Corporate Senior Vice President and Chief Accounting Officer, has been appointed interim Chief Financial Officer, effective upon Ms. Pease's departure.
• Mr. Knell, age 49, joined the Company in April 2017 and has extensive experience, including prior roles at Bruker Corporation and Ernst & Young LLP.
• The Company has commenced a comprehensive search for a permanent successor to the CFO role.
• Charles River Laboratories reaffirmed its 2025 financial guidance for revenue and non-GAAP earnings per share, previously provided on August 6, 2025, supported by its current outlook for third-quarter performance.

Sentiment

Score: 7

Explanation: The CFO's departure is a notable event, but the positive sentiment is driven by the reaffirmation of 2025 financial guidance, the amicable nature of the resignation, and the appointment of an experienced internal candidate as interim CFO, which mitigates immediate concerns about leadership stability and financial performance.

Positives

• The Company reaffirmed its 2025 financial guidance for revenue and non-GAAP earnings per share, indicating stable performance expectations despite the leadership change.
• The CFO's resignation is not due to any disagreements on financial statements, internal controls, or operations, suggesting an amicable departure.
• An experienced internal candidate, Michael G. Knell, has been appointed interim CFO, ensuring continuity and stability in the finance organization.
• Management expressed confidence in Mr. Knell's ability to lead the finance organization during the interim period due to his deep knowledge of the global business.
• The Company remains focused on executing its strategy and unlocking value for shareholders, emphasizing long-term growth opportunities and a strong market position.

Negatives

• The departure of a Corporate Executive Vice President and Chief Financial Officer introduces a degree of uncertainty regarding leadership continuity.
• The Company will incur costs and allocate resources to conduct a comprehensive search for a permanent CFO.

Risks

• Changes and uncertainties in the global economy and financial markets.
• The ability to successfully integrate businesses acquired by the Company.
• Negative trends in research and development spending, outsourced services, or other cost reduction actions by clients.
• The ability to convert backlog to revenue.
• Potential impacts from special interest groups, contaminations, industry trends, or new displacement technologies.
• Changes in USDA and FDA regulations or other laws.
• Continued availability of products and supplies.
• Loss of key personnel, including the ongoing search for a permanent CFO.
• Interest rate and foreign currency exchange rate fluctuations.
• Changes in tax regulation and laws, and changes in generally accepted accounting principles.
• Disruptions in the global economy caused by geopolitical conflicts.
• Changes in business, political, or economic conditions due to the threat of future terrorist activity.
• Ongoing legal costs in the Microbial Solutions business related to environmental litigation.
• Ongoing legal costs in the DSA segment related to U.S. government investigations into the NHP supply chain and advisory costs related to a Cooperation Agreement with a shareholder.

Future Outlook

The Company reaffirmed its 2025 financial guidance for revenue and non-GAAP earnings per share, supported by its current outlook for third-quarter performance. Management expressed confidence in executing its strategy and continuing to unlock value, leveraging its strong market position and long-term growth opportunities in early-stage drug development.

Management Comments

• "I want to thank Flavia for her three years of service and many contributions since she joined Charles River. She helped navigate the Company through a challenging demand environment and led initiatives to optimize our cost structure during this time. We wish Flavia the best in her future endeavors."
• "I would also like to thank Mike Knell for assuming the interim CFO role. Mike has been a valuable member of our management team since he joined the Company in 2017. I am confident that with his experience and deep knowledge of our global business, he is the right choice to lead our finance organization through this interim period."
• "We have launched a comprehensive search to identify a replacement and will collectively work to ensure a seamless transition of the CFO role. At the same time, we remain focused on executing our strategy and continuing to unlock value in our business."
• "We firmly believe that with our strong market position and long-term growth opportunities, we will be able to drive enhanced value creation for our shareholders and remain the partner of choice for our clients early-stage drug development needs."

Industry Context

The announcement occurs within a context where Charles River Laboratories, a key player in drug discovery and development services, has navigated a 'challenging demand environment.' The company emphasizes its 'strong market position and long-term growth opportunities' in early-stage drug development, suggesting a focus on maintaining leadership and capitalizing on the ongoing need for outsourced research and development services in the pharmaceutical and biotechnology sectors.

Management Changes

Legal Proceedings

• The Company has incurred certain legal costs in its Microbial Solutions business related to environmental litigation.
• The Company has incurred certain legal costs in its DSA segment related to U.S. government investigations into the NHP supply chain.
• The Company has incurred advisory costs related to entering into a Cooperation Agreement with a shareholder.

Related Party Transactions

• There are no related party transactions involving Mr. Knell that are reportable under Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: Potential short-term uncertainty due to CFO transition, but mitigated by reaffirmed financial guidance and experienced interim appointment.
• Employees: Leadership change in a key executive role, with an internal promotion for the interim position.
• Clients: Assurance of continuity in financial leadership and strategic focus on drug development needs.

Next Steps

• Michael G. Knell will assume the role of interim Chief Financial Officer effective September 29, 2025.
• The Company will conduct a comprehensive search to identify a permanent successor for the Chief Financial Officer position.

Key Dates

Recommendation

While the departure of a CFO can introduce uncertainty, the company's reaffirmation of its 2025 revenue and non-GAAP EPS guidance, coupled with the appointment of an experienced internal candidate as interim CFO, suggests stability in operations and financial outlook. The amicable nature of the departure also reduces immediate concerns. Investors should hold to observe the progress of the search for a permanent CFO and any subsequent strategic shifts, as the current information does not warrant a strong buy or sell action.

Keywords

CFO resignation, interim CFO, executive change, financial guidance, Charles River Laboratories, CRL, SEC filing, corporate governance, financial reporting, drug development, biotechnology